Primmune Therapeutics amasses $27.4m Series A

San Diego-based Primmune Therapeutics, a biotech company, has raised $27.4 million in Series A financing.

27 October 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles